Sirona presents new glycoprotein research for anti-ageing with hopes of European collaboration

By Andrew MCDOUGALL contact

- Last updated on GMT

Sirona presents new glycoprotein research for anti-ageing with hopes of European collaboration

Related tags: Chemical compound, Chemistry

Canada-based cosmetic ingredient firm Sirona Biochem has presented new glycoprotein research for the anti-ageing market and says the potential is there for new collaborative projects in the industry in Europe.

The company’s Chief Business Development Officer, Attila Hajdu, presented the new data from Sirona’s glycoprotein program for anti-aging and regenerative medicine, including positive efficacy data, at BIO-Europe held recently at the International Congress Centre in Munich, Germany.

The conference was provides further opportunities to engage leading companies in partnering discussions for the newest skin-lightener, SBM-TFC-1067 (1067) and the glycoprotein compounds SBM-TFC-837,1165 and 1287.

“Clearly, we have significantly progressed partnering discussions for 1067 with a select group of companies that have been testing our compound since June, including formulation testing,”​ said Attila Hajdu.

“This conference provides an opportunity to broaden the base of companies interested in licensing 1067. We were very excited about the interest from several new companies following Cosmetic 360 in Paris.”

Sirona’s 1067 ingredient is a skin lightening compound developd by its lab in Rouen, France, and the difference in comparison to the company’s earlier generation skin lightening compounds is that the chemical process of applying Sirona’s proprietary fluorination technology now requires only three steps to yield a final product.

This results in a highly favourable cost of goods (COGs) and more importantly, a product with very profitable commercial viability. A preliminary estimation of COGs for the active ingredient yielded $0.10 CAD per 100 ml final formulation at a final concentration of 0.1%.

Speaking of the ingredient, Hajdu adds that potential partners have replicated in vitro​ tests that Sirona has done in the past to double-check its efficacy and safety data, and whatever else meets their needs to justify further collaboration.

“The request for formulation testing was a pleasant surprise for us because we originally anticipated that formulation work would occur after a licensing deal. This is a very exciting development,”​ Attila continues.

In its latest announcement, Sirona says it hopes for potential new collaborative projects with cosmetic companies.

Related topics: Business & Financial

Related news

Follow us

Products

View more

Webinars